27620-10-6

Basic information

• Product Name: N-HYDROXYBUTYRAMIDINE
• Synonyms: N-HYDROXYBUTYRAMIDINE;BUTYRAMIDE OXIME;N-Hydroxybutyramidine 97%;N-Hydroxybutanamidine 97%;(1Z)-N'-hydroxybutanimidamide(SALTDATA: HCl);N-Hydroxybutanimidamide, N-Hydroxybutyramidine ,Butyramidoxime;N′-hydroxybutyrimidamide;N-Hydroxybutanamidine97%
• CAS NO: 27620-10-6
• Molecular Formula: C₄H₁₀N₂O
• Molecular Weight: 102.14
• Mol File: 27620-10-6.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 89 °C
• Flash Point: 85.4°C
• Appearance: /
• Density: 1.08g/cm³
• Vapor Pressure: 0.0282mmHg at 25°C
• Refractive Index: 1.476
• CAS DataBase Reference: N-HYDROXYBUTYRAMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-HYDROXYBUTYRAMIDINE(27620-10-6)
• EPA Substance Registry System: N-HYDROXYBUTYRAMIDINE(27620-10-6)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 27620-10-6(Hazardous Substances Data)

Usage

General Description

N-HYDROXYBUTYRAMIDINE is a chemical compound that is also known as N-hydroxybutyramide. It is a derivative of butyramide and has the molecular formula C4H9NO2. This chemical is commonly used as an intermediate in the synthesis of pharmaceuticals and organic compounds. N-HYDROXYBUTYRAMIDINE is a white solid that is soluble in water and organic solvents, and has been identified as a potential therapeutic agent for the treatment of various diseases and health conditions. Additionally, it has been studied for its potential antioxidant and anti-inflammatory properties, making it a target for further research and development in the pharmaceutical industry.

InChI:InChI=1/C4H10N2O/c1-2-3-4(5)6-7/h7H,2-3H2,1H3,(H2,5,6)

Upstream product

• 109-74-0 propyl cyanide 

Downstream Products

• 146436-68-2 5-(3-Propyl-[1,2,4]oxadiazol-5-yl)-1-trityl-1,4,5,6-tetrahydro-pyrimidine 
• 139964-24-2 methyl 4-ethyl-2-propylimidazole-5-carboxylate 
• 1037779-41-1 4-(3-(3-fluoro-4-methanesulfonylphenoxy)propyl)-1-(3-propyl-[1,2,4]oxadiazol-5-yl)piperidine 
• 1041005-90-6 C₁₇H₁₈N₆O₅ 
• 844875-56-5 C₂₈H₃₃N₅O₄ 
• 4128-37-4 1,3-diisopropylurea 
• 1041005-75-7 N-isopropyl-3-propyl-1,2,4-oxadiazol-5-amine 
• 1332498-21-1 4-[2-(3-propyl-[1,2,4]oxadiazol-5-yl)-vinyl]-benzene-1,2-diol 
• 1332498-23-3 {2-[3,4-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-vinyl}-3-propyl-[1,2,4]oxadiazole 
• 1332498-27-7 5-[2-(4-methoxy-3-nitro-phenyl)-vinyl]-3-propyl-[1,2,4]oxadiazole 

Relevant articles and documents

Copper-catalyzed one-pot synthesis of 1,2,4-triazoles from nitriles and hydroxylamine

A simple and efficient copper-catalyzed one-pot synthesis of substituted 1,2,4-triazoles through reactions of two nitriles with hydroxylamine has been developed. The protocol uses simple and readily available nitriles and hydroxylamine hydrochloride as th

OXADIAZOLE COMPOUNDS

The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1,R2,R3,L1,L2,L3,L4,L5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.

Synthesis and methemoglobinemia-inducing properties of benzocaine isosteres designed as humane rodenticides

A number of isosteres (oxadiazoles, thiadiazoles, tetrazoles and diazines) of benzocaine were prepared and evaluated for their capacity to induce methemoglobinemia - with a view to their possible application as humane pest control agents. It was found that an optimal lipophilicity for the formation of methemoglobin (metHb) in vitro existed within each series, with 1,2,4-oxadiazole 3 (metHb% = 61.0 ± 3.6) and 1,3,4-oxadiazole 10 (metHb% = 52.4 ± 0.9) demonstrating the greatest activity. Of the 5 candidates (compounds 3, 10, 11, 13 and 23) evaluated in vivo, failure to induce a lethal end-point at doses of 120 mg/kg was observed in all cases. Inadequate metabolic stability, particularly towards hepatic enzymes such as the CYPs, was postulated as one reason for their failure.